Background: Fractional flow reserve (FFR) is a "golden standard" in determining hemodynamic significance of ambiguous lesions and provides guidance on appropriateness of revascularization. The cut-off values for intravascular ultrasound (IVUS) parameters corresponding to FFR of 0.75 or 0.80 are still under investigation. The aim of this study was to determine best IVUS criteria for predicting physiological significance of left main coronary artery (LMCA) stenosis with FFR as the standard. Methods: FFR values during adenosine infusion (at the rate of 140 g/kg/min -femoral vein) were calculated in 99 patients aged 58 Ϯ 10 years with an angiographically ambiguous LMCA stenosis. Subsequently, all patients underwent IVUS with automatic pullback at a constant speed of 0.5 mm/sec., from the middle segment of left descending artery (LAD) to the aorto-ostial junction of LMCA. The following IVUS parameters were analyzed: minimum lumen area (MLA, mm 2 ), minimum lumen diameter (MLD, mm), the maximum plaque burden (PB, %), and percent area stenosis (%AS, %). Results: The averaged FFR was 0.77 Ϯ 0.10 (range 0.51-0.99). FFR Յ 0.75 was observed in 42 patients (42.4%). Linear regression analysis revealed a strong correlation between the values of FFR and MLA (AUC ϭ 0.86, p Ͻ0.001), PB (AUC ϭ 0.64, p Ͻ0.03), %AS (AUC ϭ 0.72, p Ͻ0.0002) and the MLD (AUC ϭ 0.75, p Ͻ0.0001). Cut off points for the value of FFR Յ 0.75 were: Ͻ5.9 mm 2 for MLA (sensitivity 0.69 and specificity 0.85), Ͼ59.7% for PB (sensitivity 0.77 and specificity 0.48), Ͼ 36% for %AS (sensitivity 0.94 and specificity 0.44) and Ͻ2.9 mm for MLD (sensitivity 0.97 and specificity 0.50), respectively. Conclusions: Strong correlation between FFR and LMCA lesion critical IVUS parameters was found in our patient group. MLA value of Ͻ5.9 mm 2 in IVUS seems to be a useful criterion for predicting FFR Յ 0.75.
Background: Both neoangiogenesis and inflammation contribute in atherosclerosis progression. Contrast-enhanced ultrasound (CEUS) provides visualization of plaque neovascularization. Microwave radiometry (MR) allows in vivo non-invasive measuring of temperature of tissues, reflecting inflammatory activation. We assessed the association of carotid plaque temperature, measured by MR, with plaque neovascularization assessed by CEUS. Methods: Consecutive patients with coronary artery disease and carotid atherosclerosis underwent carotid ultrasound imaging, CEUS and MR. Plaque texture, plaque surface, and plaque echogenicity were analyzed. Contrast enhancement (CE) by CEUS was defined as the % percentage of signal intensity difference, prior and post contrast infusion. Thermal heterogeneity (⌬T) was assigned as maximal temperature along the carotid artery minus minimum. Results: Eighty-six carotid arteries of 48 patients were included. Fatty plaques had higher CE% compared to mixed and calcified (21.4Ϯ2.70 versus 17.11Ϯ5.23 versus 8.55Ϯ2.42%, pϽ0.01). Heterogeneous plaques had higher CE% compared to homogenous (21.44Ϯ2.7 versus 14.66Ϯ6.02% pϽ0.01). Plaques with irregular surface had higher CE% compared to plaques with regular (18.29Ϯ5.09 versus 13.64Ϯ6.06%, pϽ0.01). Fatty plaques had higher ⌬⌻ compared to mixed and calcified (1.13Ϯ0.27 versus 0.95Ϯ0.34 versus 0.53Ϯ0.26°C, pϽ0.01). Plaques with irregular surface had higher ⌬⌻ compared to plaques with regular (1.05Ϯ0.32 versus 0.75Ϯ0.32°C, pϽ0.01). Heterogeneous plaques had higher ⌬⌻ compared to homogenous (1.13Ϯ0.27 versus 0.83Ϯ0.37°C pϽ0.01). There was a good correlation between ⌬⌻ and CE (Rϭ0.60, pϽ0.001). Conclusions: Carotid plaque neovascularization on CEUS examination is associated with increased thermal heterogeneity and ultrasound characteristics of plaque vulnerability.
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Rate of Plaque Negative to Plaque Positive Conversion in Patients by Serial 64-Slice Computed Tomography Coronary Angiography (CTCA)
Norman Lepor 1 , Laurn Contreras 1 , Philip Bretsky 1 , Gerald Friede 1 , Joel Freedman 1 , Michael Duffy 1 , Hooman Madyoon 1 1 Westside Medical Associates of Los Angeles, Beverly Hills, CA Background: This retrospective study sought to determine the conversion rate of patients from no coronary plaque to the presence of any coronary plaque using multi-slice computed tomography (MSCT). This determination may impact the intensity with which clinicians approach the treatment and follow-up of plaque-free patients with conventional coronary risk factors. Methods: Between 2004 and 2011, 241 consecutive patients were identified that underwent serial 64-slice computed tomography coronary angiography (CTCA) and coronary calcium score (CCS) studies over a mean period of 34.6 months. History of coronary atherosclerosis was evaluated through the full length of each patient's coronary tree using percent diameter stenosis (%DS), as well as through serial chart review and telephone interview to determine patient demographics, coronary artery disease risk factors, and cumulative cardiac event (coronary revascularization, non-fatal MI or stroke, death) rates during the follow-up period. Results: There were 68.5% male and 31.5% female patients, ranging from 33 to 92 years (mean: 66.5 years) and an average Framingham Risk Score of 11.1%. Of this cohort, 32 patients were observed to have no calcified or non-calcified plaque. There were 11 patients (34%) that converted to abnormal CTCAs with 10 of those patients (90%) having only calcified plaques and one of those patients (10%) with non-calcified plaques. The rate of conversion of disease from normal was observed to be 11.9% per year. Conclusions: This study indicates a strong rate of conversion from normal CTCA to the development of plaque in an intermediate risk population. These findings would indicate that a normal CTCA should not necessarily lead to a decision to withhold lipid therapy as the new presence of coronary plaque would indicate a now higher risk of coronary-related events. This is the first study of this scale to suggest a follow-up CCS should be adequate to identify the vast majority of patients who convert to plaque present. Identification of calcified plaque as the first plaque to appear on CTCA challenges the prevailing theory that the presence of calcium is indicative of an older and perhaps more plaque resistant coronary plaque.
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Coronary Plaque Regression by 64-Slice Computed Tomography Coronary Angiography (CTCA): Pipe Dream or Real Possibility
Norman Lepor 1 , Laurn Contreras 1 , Philip Bretsky 1 , Gerald Friede 1 , Joel Freedman 1 , Ivor Geft 1 , Hooman Madyoon 1 1 Westside Medical Associates of Los Angeles, Beverly Hills, CA
Background: This retrospective study sought to demonstrate coronary plaque regression in patients that underwent screening and clinically indicated serial 64-slice computed tomography coronary angiography (CTCA). MSCT has emerged as a noninvasive technique for the accurate detection of coronary artery disease in both stable and unstable patients. Methods: Between 2004 and 2011, 241 consecutive patients were identified that underwent serial 64-slice CTCA studies over a mean period of 34.6 months. History of coronary atherosclerosis was evaluated through the full length of each patient's coronary tree using percent diameter stenosis (%DS), as well as through serial chart review and telephone interview to determine patient demographics, coronary artery disease risk factors, and cumulative cardiac event (coronary revascularization, non-fatal MI or stroke, death) rates during the follow-up period. Results: There were 68.5% male and 31.5% female patients, ranging from 33 to 92 years (mean: 66.5 years) and an average Framingham Risk Score of 11.1%. Plaque regression occurred in 69 patients (29%), stability (no change) in 81 patients (34%) and progression in 91 patients (38%). Coronary artery disease regression was observed to be related to a history of coronary artery bypass (CABG) (OR: 2.7; 95% 1.2, 6.0 p ϭ0.0150), statin therapy (OR: 2.8; 95% 1.3, 6.0 p ϭ0.0065), and Vitamin D therapy (OR: 6.5; 95% 1.1, 40.8 pϭ0.0439). Of the study cohort, 45 patients underwent coronary artery bypass graft (CABG) surgery prior to their first CTCA. There were 36 patients whose CABGs remained patent. A relationship to previous CABG could be indicative of patient population that received aggressive medical therapy. Conclusions: This study indicates that coronary artery disease regression as assessed by CTCA occurs much more frequently than expected and may be related to medical therapy that includes statins and Vitamin D.
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Incidence and Morphologic Characteristics of Plaques that Evolve into Culprit Lesions: A Coronary CT Angiography Natural History Study
James Smith 1 , Ryan Madder 2 , Abhay Bilolikar 1 , JoAnne La Fleur 3 , James Goldstein 1 1 William Beaumont Hospital, Royal Oak, MI, 2 Spectrum Health, Grand Rapids, MI, 3 Georgia Health Sciences University, Augusta, GA Background: The defining morphologic characteristics of plaques that progress to culprit lesions have not been delineated. This study was undertaken to determine if plaques that evolve late to become culprit lesions have distinct morphologic features by coronary CT angiography (CTA) compared to plaques which remain quiescent. Methods: Using our CTA database, we studied patients undergoing CTA for any reason who were ultimately determined not to have a culprit lesion. From this population, we identified patients who subsequently presented with acute coronary syndrome (ACS) Ͼ45 days later, and were found to have a new culprit lesion by invasive angiography. Among these patients, the index CTA was analyzed in a blinded fashion for plaque morphology. The morphologic characteristics of plaques which evolved into culprits were compared to those which remained clinically silent. Results: Among 4,459 patients undergoing CTA, a total of 9,718 plaques were present. There were 24 patients who subsequently developed ACS Ͼ45 days (mean 409Ϯ324 days) after the index CTA. Therefore, the incidence of patients developing ACS was 0.5%, and the rate of plaques evolving into culprit lesions was 0.26%. Analysis of the index CTA revealed that plaques that evolved into culprits were frequently positivelyremodeled (68%) and were composed of low-attenuation plaque (21 Ϯ 21 mm 3 ). 
